Skip to content
lifestyle.childcarepartnerships.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
CorMedix, Inc.
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
October 19, 2026
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
September 1, 2026
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
July 29, 2026
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
June 8, 2026
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
May 15, 2026
Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026
May 5, 2026
CorMedix Therapeutics Announces Positive Topline Results from Phase III ReSPECT Trial Assessing REZZAYO® for the Prophylaxis of Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplantation Patients
April 27, 2026